Page 19 - Emergent Biosolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Home / Top News / EBS INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – EBS EBS INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – EBS NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through Ma...

Share this article NEW YORK, May 4, 2021 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Emergent BioSolutions class act...

A Maryland-based vaccine producer is expanding its late-stage Phase 3 clinical trial study to include children ages 12 to 17.

What a decade of inspection reports shows about firm tasked with helping make vaccine Johnson & Johnson manufacturer’s embattled history with the FDA Replay Video UP NEXT Even as shots of the Johnson & Johnson COVID-19 vaccine resume across the country following a recent federally-recommended pause, new manufacturing at a key facility tasked with helping make the vaccine is still on hold. Emergent BioSolutions -- the company whose Baltimore-area plant had been developing a key component for both Johnson & Johnson and AstraZeneca -- accidentally cross-contaminated and ruined up to 15 milli...

NEW YORK, April 29, 2021 /PRNewswire/ --